C)-choline PET/computed tomography (CT) has shown good results in re-staging of prostate cancer
(PCa) with raised serum levels of prostate-specific antigen. Our aim was to evaluate the effect of positive 11
results in the therapeutic management
of patients with PCa with biochemical relapse
(BR) after curative intention treatment.
Patients and methods
A total of 112 patients with PCa BR and positive 11
were retrospectively evaluated. PET/CT
was acquired 20 min after intravenous administration of 555–740 MBq of 11
C-choline. The therapeutic management
was obtained from the clinical records. The minimum follow-up time was 18 months.
In 80 (71.4%) of 112 patients, 11
showed local recurrence of PCa; in 17 (15.2%) patients, distant recurrence; and in 15 (13.4%) patients, local plus distant recurrence. A second malignancy was detected in five (4.5%) patients. The planned therapeutic management
was changed as per positive 11
result in 74 (66.1%) patients and were treated as follows: 31 (27.7%) patients with HT, combined with other treatments in eight (7.1%), 17 (15.2%) with BT, 13 (11.6%) with external beam radiotherapy, one (0.9%) with RP, and four (3.6%) with chemotherapy. Treatment approach was not modified in 37 (33%) patients. No data was available from one (0.9%) patient.
result had an important effect in the therapeutic management
of patients with PCa and BR, leading to a change in the planned approach in two (66.1%) out of three patients. In addition, in 4.5% of the patients, the 11
allowed the detection of a second malignancy.